The effects of clinical, laboratory, and angiographic factors on stent thrombosis and major adverse cardiac events in paclitaxel eluting stents

Abstract

Background: Drug-eluting stents (DES) have higher marked efficacy and lower revascularization requirements compared to bare metal stents (BMS).We aimed to determine the mid-term outcomes of patients implanted with a first-generation DES "paclitaxel-eluting stents" (PES). Methods: Patients with at least 1 PES implanted in our cardiology clinic were received in the non-randomized group. Inclusion criteria were all patients undergoing percutaneous coronary intervention and PES implantation. The mean follow-up time was 35.14 + 13.4 months. Results: A total of 302 patients (401 lesions and 337 PES) were enrolled in the study. The mean age was 61.86 + 10.27 years. Major adverse cardiac and cerebrovascular events (MACE) occurred at 17.9%, and the stent thrombosis rate was 4%. Independent predictors of stent thrombosis were serum creatinine levels [OR 1.59; 95% CI, 1.03-2.46, p = 0.03] and mean platelet volume [OR 1.59; 95% CI, 1.03-2.46, p = 0.03]. Also, poor functional capacity [OR 2.46: 95% CI, 1.42-4.26, p < 0.001] and positive ischemia test [OR 3.43: 95% CI, (1.73-6.82), p < 0.001] were predictors of MACE's. Conclusions: We have demonstrated that PES is safe and effective in the mid-term for use in coronary artery disease